Price
38.14
-2.08%52W Range
Market Cap
₹2,473.44 Cr
Traded: ₹3.30 Cr (0.13%) 0.0x
Free Float: ₹518.68 Cr (0.64% of FF traded)
Volume · 60D trend
8.63 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | -- | +1097.0% | -- | +196.0% | Decelerating |
| ROE | -- | -- | +6.0% | -- | -- | -- |
| Return | +71.0% | +37.0% | +57.0% | -61.0% | -- | Stable |
| Profit | -- | -- | +820.0% | -- | +286.0% | Decelerating |
Quarterly Results
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Sep 2023PDF ↗ | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 82 | 98 | 101 | 86 | 23 | 49 | 12 | 40 | 10 | 21 | 0 |
| Expenses | 71 | 101 | 80 | 70 | 19 | 47 | 11 | 39 | 10 | 18 | 0 |
| Operating Profit | 11 | -4 | 22 | 16 | 4 | 3 | 0 | 1 | -0 | 3 | 0 |
| OPM % | 13.7% | -3.9% | 21.3% | 18.8% | 17.0% | 5.1% | 3.1% | 1.3% | -2.1% | 12.1% | -- |
| Other Income | 1 | 1 | 1 | 2 | 7 | 0 | 0 | 0 | 1 | 0 | 0 |
| Interest | 4 | 4 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 8 | -8 | 21 | 17 | 10 | 2 | 0 | 0 | 0 | 3 | 0 |
| Tax % | 51.6% | 64.0% | 9.2% | 19.5% | 51.5% | 26.0% | 350.0% | -38.1% | 271.4% | 6.2% | -- |
| Net Profit | 4 | -12 | 19 | 14 | 5 | 1 | -0 | 0 | -0 | 3 | 0 |
| Exceptional Items | -- | 0 | 0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 |
| EPS (Rs) | 0.1 | -0.2 | 0.3 | 0.2 | 0.1 | 0.0 | -0.0 | 0.0 | 0.0 | 0.1 | 0.0 |
| Sales Growth (YoY) | 249.5% | 98.4% | 760.4% | 117.6% | 131.6% | 136.5% | -- | -- | -- | -- | -- |
| Sales Growth (QoQ) | -16.0% | -3.5% | 17.1% | 268.2% | -52.3% | 318.5% | -70.4% | 291.9% | -51.3% | -- | -- |
| OP Growth (YoY) | 182.0% | -250.2% | 5729.7% | 3144.0% | 2000.0% | 0.0% | -- | -- | -- | -- | -- |
| OP Growth (QoQ) | 398.4% | -117.5% | 33.0% | 306.5% | 59.0% | 578.4% | -26.0% | 338.1% | -108.4% | -- | -- |
| Profit Growth (YoY) | -- | -642.0% | 6731.0% | 2922.0% | 2635.0% | -49.0% | -- | -- | -- | -- | -- |
| EPS Growth (YoY) | -14.3% | -1050.0% | 3100.0% | 2000.0% | -- | -60.0% | -- | -- | -- | -- | -- |
| EPS Growth (QoQ) | 131.6% | -163.3% | 42.9% | 200.0% | 250.0% | 300.0% | -200.0% | -- | -100.0% | -- | -- |
| OP Margin | 13.7% | -3.9% | 21.3% | 18.8% | 17.0% | 5.1% | 3.1% | 1.3% | -2.1% | 12.1% | -- |
| Net Margin | 4.6% | -12.8% | 19.0% | 16.1% | 20.7% | 2.7% | -2.5% | 0.7% | -1.2% | 12.5% | -- |
| Material Cost % | -- | 70.0% | 48.0% | 15.0% | 54.0% | 80.0% | 64.0% | 91.0% | 85.0% | 79.0% | -- |
| Employee Cost % | -- | 4.0% | 4.0% | 4.0% | 13.0% | 2.0% | 6.0% | 1.0% | 4.0% | 2.0% | -- |
| P/S | 6.74 | 8.12 | 9.55 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 100.37 | 80.50 | 62.52 | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 6.44 | 6.53 | 6.87 | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & Others
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & PACs
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & Others
Allotment of equity shares pursuant to conversion of warrants
Allotment of equity shares pursuant to conversion of warrants
Approval of Q 1 financial results for FY 2026-27
Resgination of Independent Directors
Approval of Q 1 financial results FY 2026-27 in alia, considered other matters.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & PACs
Monitoring Agency Report for quarter ended 30th June 2026
Allotment of equity shares pursuant to conversion of warrants
Allotment of Equity shares pursuant to Conversion of warrants.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & PACs
Allotment of 23,00,000 Equity shares pursuant to conversion of warrants
Newspaper Advt- Special Window for Re-lodgement of Transfer Request for Physical Shares
Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve un-audited financial ....
Certificate under Reg 74(5) of SEBI(DP) Regulations,2018 for quarter ended 30th June 2026
Closure of Trading Window for Q1 financial results
Newspaper Publication for Share Transfer related
Financial Results for the Quarter and Year ended 31.03.2026
Recommendation of Final Dividend
Financial Results
Outcome of BM
Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve i) to consider and ....
Monitoring Agency Report for the quarter ended 31-03-2026
Newspaper Advertisement- Special Window for Re-lodgement of Transfer requests for physical shares
Press Release on landmark collaboration with WFNS Innovation and Time Medical International Ventures (India) Pvt Ltd, a WOS of Fischer Medical Ventures Limited.
Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for Q4-31.03.2026.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shankar Varadharajan & PACs
Allotment of equity shares upon conversion of warrants
Trading Window Closure for 31st March 2026
Appointment of Company Secretary and Compliance Officer
Intimation for closure of Trading Window
Newspaper advertisement enclosed
Update on Investment made by the subsidiary of the Company
Monitoring Agency Report for Q3
Launch of 1.5T MRI platforms- MICA and QUIN at IRIA-2026
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on February ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on February 06, 2026 for Shankar Varadharajan
Outcome of the Board meeting held on 30/01/2026
Announcement under Reg 30- Resignation of Company Secretary
Intimation under Reg-30 from Material Subsidiary
Outcome of the Board Meeting held on 30/01/2026 and Q3 Results
Announcement under Regulation 30(LODR)
Fischer Medical Ventures Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve The unaudited Standalone ....
Fischer Medical Ventures Limited informed the exchange on General update
Intimation of Copy Newspaper publication
Intimation of Certificate under Reg 74(5) of SEBI DP Regulations
Intimation of reconstitution of Committees of the Board
Intimation of trading window closure
Annual Reports
15Concalls
2Nov 2025
30 Nov 2025Dec 2024
31 Dec 2024Held by Mutual Funds
2 schemes hold fischer · sorted by weight